Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review
Executive Summary
FDA requested that Merck conduct an additional study in primates during its review of Januvia (sitagliptin) due to concerns of necrotoxicity that were based on similar findings seen with other DPP-4 inhibitors
You may also be interested in...
Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?
The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best
Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?
The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best
Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay
Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested